Viewing nowLureca Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Huons Life Science Co., Ltd.

MFDS item code 202003561 · Approved 2020.05.15 · Insurance code 052701460
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunct for partial seizures in epilepsy patients. Additionally, it is effective in alleviating symptoms of fibromyalgia. In summary, this medication is used for the treatment of neuropathic pain, partial seizures in epilepsy, and fibromyalgia.
This medication is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Because this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and may be increased to 150 mg twice daily (300 mg/day) within 1 week based on efficacy and tolerability. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *For women, multiply the result obtained from the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration schedule Initial dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30-<60 75 300 BID or TID ≥15-<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the administration schedule. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: As there are insufficient data on safety and efficacy, administration is not recommended. Adolescent patients aged 12-17 years: As there are insufficient data on safety and efficacy, administration is not recommended.
This medication may increase the risk of suicidal thoughts or behaviors; therefore, if there are any changes in mood or unusual behavior during treatment, consult a doctor immediately. Do not use this medication if you are allergic to any of the components or have specific genetic lactose intolerance disorders. Diabetes patients should be cautious as weight gain may require adjustments in blood sugar control medications. If severe allergic reactions such as angioedema occur, discontinue the medication immediately and inform healthcare personnel. Elderly patients may experience dizziness, drowsiness, or confusion while taking this medication, so caution is advised, and driving or operating dangerous machinery should be avoided in such instances. This medication may cause temporary blurred vision or visual changes, so consult a doctor if you experience any vision abnormalities. If this medication is suddenly discontinued, withdrawal symptoms like insomnia, headache, and anxiety may arise, so tapering off should be done according to the doctor's instructions. There is a risk of drug abuse; thus, patients with a history of drug abuse or mental illness should be particularly cautious. Patients with reduced kidney function may require dose adjustments, and those with heart disease should use this medication with caution. When combined with other medications that have central nervous system depressant effects, the risk of respiratory depression may increase, so inform healthcare personnel about all medications taken and exercise caution. In early pregnancy, it may affect the fetus, so women who are pregnant or planning to become pregnant should consult a doctor before use and ensure effective contraceptive methods are used. Breastfeeding women should consult a doctor regarding the use of this medication since it can be transmitted through breast milk and may affect the baby. In cases of overdose, symptoms such as confusion, drowsiness, and depression may occur; treatment may include blood dialysis if necessary. Store this medication out of reach of children and take care not to transfer it to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a well-sealed container to prevent exposure to air and moisture, ideally at room temperature between 15 and 30 degrees Celsius. Doing so will help maintain its efficacy and prevent degradation.
Hard capsule containing white powder in upper and lower parts of white color
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Huons Life Science Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.